Fennec Pharms

FENC NASDAQ
4.350
+0.020
+0.46%
盘后: 4.350 0 0.00% 17:00 08/16 EDT
开盘
4.360
昨收
4.330
最高
4.490
最低
4.305
成交量
6,455
成交均量(3M)
9.10万
52周最高
10.19
52周最低
3.255
换手率
0.04%
市值
8,010.31万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Fennec Pharms FENC股票价格,Fennec Pharms股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
展开 >

最近浏览

名称
价格
涨跌幅